CHF submitted this response to the House of Representatives Standing Committee on Health, Aged Care and Sport inquiry into approval processes for new drugs and novel medical technologies in Australia June 2021.

The recommendations, which include feedback from health consumers who are members of CHF’s safety and quality special interest group, confirm that streamlining processes, working collaboratively with consumers and consumer organisations, embracing personalised medications, research and health technologies, supporting equitable access and the revision of the National Medicines Policy are all timely and necessary.

The full submission is available below.